The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
No Access

Psychostimulants in post-stroke depression

Published Online:https://doi.org/10.1176/jnp.3.1.23

The hospital charts of 17 patients with post-stroke depression who were treated with either dextroamphetamine or methylphenidate during a 5- year period at the Massachusetts General Hospital were examined. Eighty- two percent of the patients showed improvement after psychostimulant treatment. Forty-seven percent of all patients showed marked or moderate improvement in depressive symptoms. The authors saw no significant differences in efficacy between the two psychostimulants or across the diagnostic categories for depression. Patients improved quickly, usually within the first 2 days of treatment. Adverse reactions necessitating the termination of psychostimulant treatment occurred in three patients. Anorexia was not observed as a side effect of either dextroamphetamine or methylphenidate treatment. Psychostimulants appear to be a safe and rapidly effective alternative to tricyclic antidepressants in inpatients with post-stroke depression.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.